ArticleInflammopharmacology2026
A potent and selective P2 × 7R antagonist ameliorates neuropathic pain by suppressing inflammation and oxidative stress in a mouse chronic constriction injury model.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropathic pain is an unpleasant condition that involves neuroinflammation and oxidative stress following injury to peripheral nerves. Recently, P2 × 7R, an ATP-gated channel, has been shown to play a role in the pathogenesis of neuropathic pain. Hence, we investigated the role of a potent and selective P2 × 7R antagonist in the amelioration of neuropathic pain in a mouse model of chronic constriction injury (CCI). Mice were randomly divided into five groups, namely: sham, CCI, CCI + P2 × 7R antagonist (2.5 mg/kg), CCI + P2 × 7R antagonist (0.5 mg/kg), and CCI + pregabalin (5 mg/kg). Behavioral assessments included the open field test for locomotor activity, von Frey filaments, and hot-plate tests for assessment of mechanical and thermal hyperalgesia, respectively. Sciatic nerve and spinal cord tissue samples were analyzed for inflammatory cytokines (TNF-α, IL-1β, IL-6, NF-κB), oxidative stress markers (catalase, GSH, GST, LPO), and histopathology. It was observed that the CCI group demonstrated significantly reduced locomotor activity along with reduced thresholds for mechanical and thermal hyperalgesia compared with control animals. This was also associated with a marked increase in the expression of the pro-inflammatory cytokines, including TNF-α, IL1β, IL-6, and NF-κB in these tissues. Interestingly, repeated treatment with P2 × 7R antagonist and pregabalin significantly reversed pain behavior, along with suppression of neuroinflammation, dose- dependently. Further, P2 × 7R antagonist treatment restored BDNF, PPAR-γ levels, antioxidant defenses, and histological degenerations in sciatic nerve and spinal cord tissues. Together, these findings demonstrate that pharmacological antagonism of P2 × 7R effectively alleviates neuropathic pain related behavior while exerting potent anti-inflammatory, antioxidative, and neuroprotective actions in the CCI model.
Indexed as
Identifiers
42307827What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.